Literature DB >> 26165400

Short Communication: Practical Experience with Analysis and Design of Repeat Low-Dose SHIVSF162P3 Exposure Studies in Female Pigtail Macaques with Varying Susceptibility During Menstrual Cycling.

Ellen N Kersh1, Tara R Henning1, Charles Dobard1, Walid Heneine1, Janet M McNicholl1.   

Abstract

Vaginal SHIVSF162P3 acquisition in pigtail macaques (Macaca nemestrina) is dependent on time point during the menstrual cycle. Susceptibility is higher around menstruation and lower at ovulation in mid cycle. This complicates the design of repeat low-dose (RLD) SHIV exposure studies because virus challenges given during low susceptibility periods have lower chances to infect. To account for fluctuating susceptibility, we analyzed menstrual cycles rather than exposures until infection following virus challenges. We first reanalyzed infection data of 41 macaques receiving placebo or no treatment during once (n=18) or twice (n=23) weekly virus exposures. The same number of cycles was required for infection with either challenge frequency, while it took a median four or six challenges for once or twice weekly exposures, respectively. More virus challenges to infection likely reflect frequent unsuccessful exposures in frequently exposed animals. When reanalyzing two previously reported biomedical HIV intervention studies, we found 1% tenofovir gel was 74% or 86% efficacious based on cycles or exposures (p=0.019 or p=0.003, respectively, Fisher's exact test), while 1% raltegravir gel was 84% or 89 % efficacious, respectively (p=0.047 or p=0.031). Evaluating the number of menstrual cycles rather than exposures until infection can account for varying susceptibility during the menstrual cycle. Our observations have implications for future study designs such as planning the frequency of virus exposures. Menstrual cycle analysis may also avoid potential overestimation of efficacy against vaginal challenges during low susceptibility periods in the cycle that are unlikely to cause infection.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26165400      PMCID: PMC4636932          DOI: 10.1089/AID.2014.0373

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  19 in total

1.  High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques.

Authors:  Sundaram A Vishwanathan; Patricia C Guenthner; Carol Y Lin; Charles Dobard; Sunita Sharma; Debra R Adams; Ron A Otten; Walid Heneine; R Michael Hendry; Janet M McNicholl; Ellen N Kersh
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-01       Impact factor: 3.731

2.  Characteristics of the menstrual cycle in nonhuman primates. IV. Timed mating in Macaca nemestrina.

Authors:  G B Blakley; T W Beamer; W R Dukelow
Journal:  Lab Anim       Date:  1981-10       Impact factor: 2.471

3.  Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates.

Authors:  Ron A Otten; Debra R Adams; Caryn N Kim; Eddie Jackson; Jennifer K Pullium; Kemba Lee; Lisa A Grohskopf; Michael Monsour; Sal Butera; Thomas M Folks
Journal:  J Infect Dis       Date:  2004-12-09       Impact factor: 5.226

4.  Hormonal synchronization of the menstrual cycles of pigtail macaques to facilitate biomedical research including modeling HIV susceptibility.

Authors:  Lindsay Livingston; Elizabeth Sweeney; James Mitchell; Wei Luo; Katherine Paul; Nathaniel Powell; R Michael Hendry; Janet McNicholl; Ellen Kersh
Journal:  J Med Primatol       Date:  2011-01-17       Impact factor: 0.667

5.  Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments.

Authors:  Michael G Hudgens; Peter B Gilbert; John R Mascola; Chih-Da Wu; Dan H Barouch; Steven G Self
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

6.  Assessing vaccine effects in repeated low-dose challenge experiments.

Authors:  Michael G Hudgens; Peter B Gilbert
Journal:  Biometrics       Date:  2009-12       Impact factor: 2.571

7.  Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.

Authors:  Urvi M Parikh; Charles Dobard; Sunita Sharma; Mian-er Cong; Hongwei Jia; Amy Martin; Chou-Pong Pau; Debra L Hanson; Patricia Guenthner; James Smith; Ellen Kersh; J Gerardo Garcia-Lerma; Francis J Novembre; Ron Otten; Thomas Folks; Walid Heneine
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

8.  Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates.

Authors:  Adrian B McDermott; Jacque Mitchen; Shari Piaskowski; Ivna De Souza; Levi J Yant; Jason Stephany; Jessica Furlott; David I Watkins
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Macaca fascicularis vs. Macaca nemestrina as a model for topical microbicide safety studies.

Authors:  Dorothy L Patton; Yvonne C Sweeney; Che-Chung Tsai; Sharon L Hillier
Journal:  J Med Primatol       Date:  2004-04       Impact factor: 0.667

10.  Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.

Authors:  Roland R Regoes; Ira M Longini; Mark B Feinberg; Silvija I Staprans
Journal:  PLoS Med       Date:  2005-07-19       Impact factor: 11.069

View more
  2 in total

1.  A Depot Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV Acquisition Risk.

Authors:  Katherine Butler; Jana M Ritter; Shanon Ellis; Monica R Morris; Debra L Hanson; Janet M McNicholl; Ellen N Kersh
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

Review 2.  Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences.

Authors:  Gregory Q Del Prete; Jeffrey D Lifson; Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2016-11       Impact factor: 4.283

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.